Keyphrases
Chemoresistance
100%
Pancreatic Ductal Adenocarcinoma
100%
Poor Prognosis
100%
IRAK4
100%
NF-B
75%
Phosphorylation State
37%
Pancreatic Duct Cells
37%
Interleukin-1β
25%
Toll-like
25%
Transcription Factor
25%
Inflammatory Cytokines
12%
Apoptosis
12%
Tissue Microarray
12%
Overall Survival
12%
Receptor Signaling
12%
Gemcitabine
12%
Human Pancreatic Ductal Adenocarcinoma
12%
Behavioral Outcomes
12%
Poor Outcome
12%
Small Molecules
12%
Pharmacologic
12%
Cell Tumor
12%
Strong Correlation
12%
Cytokine Production
12%
RNA Interference
12%
Master Regulator
12%
Genetic Ablation
12%
Therapeutic Effect
12%
Aggressive Behavior
12%
Tumor Cell Proliferation
12%
Functional Studies
12%
Pathobiology
12%
Surgical Specimen
12%
Novel Therapeutic Targets
12%
Adenocarcinoma Cells
12%
Clinical Testing
12%
IL-1 Receptor-associated Kinase 1 (IRAK1)
12%
Anchorage-independent Growth
12%
CRISPR-Cas9n
12%
IRAK4 Inhibitor
12%
Postoperative Relapse
12%
Tumor Fibrosis
12%
Immunology and Microbiology
Drug Resistance
100%
Transcription Factors
66%
Interleukin 1
66%
Toll-Like Receptor
66%
Secretion (Process)
33%
Tumor Cell
33%
Overall Survival
33%
Proinflammatory Cytokine
33%
Cell Proliferation
33%
Cytokine Production
33%
Clustered Regularly Interspaced Short Palindromic Repeat
33%
Adenocarcinoma Cell Line
33%
IRAK1
33%
Anchorage Independent Growth
33%
RNAI
33%
Programmed Cell Death
33%
Biochemistry, Genetics and Molecular Biology
Drug Resistance
100%
IRAK4
100%
Transcription Factors
22%
Interleukin-1
22%
Toll-Like Receptor
22%
Secretion (Process)
11%
Overall Survival
11%
Cell Proliferation
11%
Genetic Ablation
11%
Cytokine Production
11%
CRISPR
11%
Proinflammatory Cytokine
11%
Tissue Microarray
11%
Anchorage Independent Growth
11%
Aggression
11%
IRAK1
11%
RNAI
11%
Gemcitabine
11%
Programmed Cell Death
11%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Resistance
100%
Pancreas Adenocarcinoma
100%
Neoplasm
16%
Cytokine
16%
Interleukin 1
16%
Transcription Factors
16%
Toll Like Receptor
16%
Overall Survival
8%
Fibrosis
8%
Therapeutic Effect
8%
Gemcitabine
8%